Marksans Pharma Ltd

Marksans Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Marksans Pharma Ltd

₹ 173 3.23%
26 Apr 1:25 p.m.
marksanspharma.com BSE: 524404 NSE : MARKSANS
About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.

Our key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others. [1]

Key Points

Revenue Mix
Revenue Mix by therapeutic wise FY23[1]
Pain Management : 44%
Cough & Cold : 14%
Cardiovascular System : 9%
CNS: 8%
Anti-diabetic : 2%
Gastrointestinal : 9%
Others : 14%

Website BSE NSE
  • Market Cap ₹ 7,819 Cr.
  • Current Price ₹ 173
  • High / Low ₹ 186 / 70.2
  • Stock P/E 66.0
  • Book Value ₹ 25.7
  • Dividend Yield 0.30 %
  • ROCE 14.9 %
  • ROE 11.4 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 52.6% CAGR over last 5 years

Cons

  • Earnings include an other income of Rs.54.2 Cr.
  • Company has high debtors of 170 days.
  • Promoter holding has decreased over last 3 years: -4.40%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
168 138 147 169 166 176 159 170 173 153 182 205 241
134 111 122 135 138 149 148 136 149 130 155 167 199
Operating Profit 35 27 25 34 28 27 12 34 24 23 27 37 42
OPM % 21% 19% 17% 20% 17% 15% 7% 20% 14% 15% 15% 18% 17%
6 12 14 9 12 8 19 21 16 4 33 16 1
Interest 1 2 1 1 1 1 1 1 1 1 0 0 0
Depreciation 4 4 4 4 5 5 5 5 4 4 5 8 8
Profit before tax 36 32 34 37 35 29 26 49 34 23 54 44 35
Tax % 19% 27% 15% 25% 25% 25% 25% 18% 26% 22% 19% 30% 27%
29 24 29 28 26 21 19 40 26 18 44 31 25
EPS in Rs 0.71 0.58 0.71 0.67 0.64 0.52 0.47 0.99 0.64 0.39 0.98 0.69 0.56
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
155 192 315 406 358 216 295 424 433 600 658 655 781
272 148 231 290 254 191 266 361 362 486 545 563 652
Operating Profit -118 44 84 116 104 24 29 63 71 114 114 92 129
OPM % -76% 23% 27% 29% 29% 11% 10% 15% 16% 19% 17% 14% 16%
2 4 3 3 9 7 7 8 0 31 42 60 54
Interest 49 10 15 13 6 4 8 7 7 5 4 4 1
Depreciation 18 9 9 9 15 15 12 9 12 15 18 17 25
Profit before tax -183 30 63 97 92 12 17 56 53 124 135 132 156
Tax % 1% -34% 12% 31% 22% 3% 25% 22% 28% 21% 23% 22%
-181 40 56 67 71 12 12 44 38 98 104 103 119
EPS in Rs 1.03 1.44 1.64 1.75 0.28 0.30 1.07 0.93 2.40 2.54 2.27 2.62
Dividend Payout % 0% 0% 7% 7% 7% 18% 16% 5% 11% 10% 10% 22%
Compounded Sales Growth
10 Years: 13%
5 Years: 17%
3 Years: 15%
TTM: 15%
Compounded Profit Growth
10 Years: 10%
5 Years: 53%
3 Years: 40%
TTM: 11%
Stock Price CAGR
10 Years: 21%
5 Years: 47%
3 Years: 34%
1 Year: 106%
Return on Equity
10 Years: 13%
5 Years: 13%
3 Years: 15%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 37 39 39 41 41 41 41 41 41 41 41 45 45
Reserves -240 58 108 305 369 378 388 430 465 559 651 1,066 1,118
Preference Capital 14 14 14 12 12 0 0 0 0 0 0 0
100 91 89 50 41 73 67 78 11 14 14 8 9
345 123 141 132 83 54 61 64 83 127 260 226 225
Total Liabilities 243 310 376 527 534 546 557 612 600 741 966 1,345 1,398
77 73 67 90 97 94 88 103 115 129 136 144 225
CWIP 0 0 0 0 0 0 0 0 0 0 0 4 0
Investments 24 68 68 68 231 234 236 236 236 236 237 266 266
142 170 242 369 205 217 233 273 249 375 594 931 907
Total Assets 243 310 376 527 534 546 557 612 600 741 966 1,345 1,398

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-61 9 54 112 65 -14 16 20 108 107 56 52
41 -48 -2 -29 -177 -8 -8 -20 -24 9 -128 -195
11 22 -19 51 -52 21 -10 1 -82 -14 71 210
Net Cash Flow -9 -17 33 134 -164 -1 -2 1 2 102 -1 67

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 175 174 130 112 136 262 209 153 136 103 137 170
Inventory Days 167 182 120 85 90 95 91 109 111 101 100 121
Days Payable 123 106 87 75 64 67 73 58 84 69 72 103
Cash Conversion Cycle 220 250 163 123 161 290 228 204 163 135 165 188
Working Capital Days -484 101 82 69 133 300 232 193 147 94 116 144
ROCE % 71% 35% 33% 22% 3% 5% 12% 11% 23% 21% 15%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
48.25% 48.25% 48.25% 48.25% 48.25% 48.60% 49.00% 43.85% 43.85% 43.85% 43.85% 43.85%
3.14% 2.64% 2.59% 3.46% 4.04% 4.06% 4.23% 15.11% 14.90% 15.07% 15.55% 15.57%
0.56% 0.53% 0.41% 0.47% 0.94% 0.95% 0.96% 1.46% 3.65% 4.02% 4.76% 5.17%
48.05% 48.58% 48.75% 47.82% 46.77% 46.38% 45.79% 39.57% 37.60% 37.06% 35.81% 35.40%
No. of Shareholders 1,88,8882,01,4512,14,9982,20,0902,21,3592,17,7432,13,1231,98,3821,88,4472,07,9372,37,3772,54,699

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls